Zelnorm may be gone, but there is a new kid in town. The FDA just announced that it has approved Amitiza for the treatment of constipation predominant irritable bowel syndrome (IBS-C) in women who are over the age of 18. Amitiza is thus the only prescription medicine approved by the FDA for IBS-C.

Amitiza had previously been approved for the treatment of chronic idiopathic constipation (CIC), which is basically IBS without pain. Interestingly enough, the dosage for CIC is higher than that for IBS-C. Amitiza has not been approved for use by men or children and should not be prescribed to women who are nursing or breast-feeding, or anyone who experiences diarrhea or a bowel obstruction.

For more on Amitiza, see:

Prescription Medication for Constipation Predominant IBS

Do you have any experience with Amitiza? Share your story on the IBS discussion forum!

_Source:

FDA Approves Amitiza for IBS-C